ACRS
Aclaris Therapeutics Inc
Price:  
2.01 
USD
Volume:  
726,098.00
United States | Pharmaceuticals
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

Aclaris EV/EBITDA

-304.4%
Upside

As of 2025-10-21, the EV/EBITDA ratio of Aclaris Therapeutics Inc (ACRS) is -3.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Aclaris's latest enterprise value is 217.74 mil USD. Aclaris's TTM EBITDA according to its financial statements is -55.46 mil USD. Dividing these 2 quantities gives us the above Aclaris EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 5.1x - 8.8x 6.2x
Forward P/E multiples 7.7x - 12.8x 9.8x
Fair Price (3.92) - (4.48) (4.11)
Upside -295.1% - -323.1% -304.4%
2.01 USD
Stock Price
(4.11) USD
Fair Price

Aclaris EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA